



Haemoglobinopathies with high oxygen affinity. Experience of Erythropathology Cooperative Spanish Group

F. A. González Fernández, A. Villegas, P. Ropero, M. D. Carreño, E. Anguita,
M. Polo, A. Pascual, A. Henández

► To cite this version:

F. A. González Fernández, A. Villegas, P. Ropero, M. D. Carreño, E. Anguita, et al.. Haemoglobinopathies with high oxygen affinity. Experience of Erythropathology Cooperative Spanish Group. Annals of Hematology, 2008, 88 (3), pp.235-238. 10.1007/s00277-008-0581-x . hal-00477972

HAL Id: hal-00477972

<https://hal.science/hal-00477972>

Submitted on 30 Apr 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Haemoglobinopathies with high oxygen affinity. Experience of Erythropathology Cooperative Spanish Group

F. A. González Fernández · A. Villegas · P. Ropero ·
M. D. Carreño · E. Anguita · M. Polo · A. Pascual ·
A. Henández

Received: 5 September 2007 / Accepted: 28 July 2008 / Published online: 26 September 2008
© Springer-Verlag 2008

Abstract Haemoglobinopathies are the world's most frequently found monogenic disorders. In the cases with high oxygen affinity, the decrease in the liberation of the oxygen determines a secondary erythrocytosis. In this work, we present 17 unrelated families of Caucasian race and of Spanish origin, with ten variants of haemoglobin or haemoglobinopathies with high oxygen affinity which were diagnosed in our laboratory. Of the ten haemoglobinopathies, in four (the Hb San Diego, the Hb Johnstown, the Hb Malmö and the Hb Columbia-Missouri), the change of amino acid affects zones of the contact $\alpha_1\beta_2$; in two variants (the Hb Strasbourg and the Hb Syracuse), it affects the unions with 2,3-DPG in the central cavity; in the other two (the Hb Badalona and the Hb La Coruña), the cavity of contact with the group haem is affected; in one (Hb Bethesda), it affects the zone of contact $\alpha_1\beta_1$; and in one (Hb Olympia), the position 20 of the chain in the helix B in the surface of the protein is affected. In all cases, the change of amino acid, though of different form, facilitates that the quaternary structure of the haemoglobin becomes stable in its relaxed configuration so the transfer of oxygen and the P_{50} value are decreased. All cases were sent to our laboratory because of shown erythrocytosis. In the majority of them, the diagnosis was done during an analysis of routine or for being relatives of the first ones.

F. A. González Fernández · A. Villegas · P. Ropero ·
M. D. Carreño · E. Anguita · M. Polo · A. Pascual · A. Henández
Servicio de Hematología, Hospital Clínico San Carlos,
Madrid, Spain

F. A. González Fernández (✉)
Servicio de Hematología y Hemoterapia,
Hospital Clínico San Carlos,
Madrid, C/ Profesor Martín Lagos s/n,
28040 Madrid, Spain
e-mail: fgonzalezf@aehh.org

Keywords Haemoglobinopathies · High oxygen affinity

Introduction

Haemoglobinopathies are the world's most frequently found monogenic disorders [1]. Single mutations, deletions or insertions in the genes that encode globin chains may lead to qualitative alteration of the genes' expression in structural haemoglobinopathies or to a reduced or nonexistent expression, as seen in thalassaemia [2].

So far, over 900 haemoglobin structural variations have been described. The structural alteration is due to a single amino acid replacement in over 95% of these variants. Depending on the replaced amino acid nature and its location, changes will be observed in the haemoglobin molecules' stability, solubility and function that finally lead to clinical haemoglobinopathies. Polyglobulia, generated to compensate for a decrease in the O_2 released into tissues, when the amino acid replacement increases Hb affinity for oxygen (O_2), is one of the clinical conditions that can be found [3]. Up to now, 89 haemoglobinopathies that show high oxygen affinity have been described. Only 18 of them affect one of the α genes and 71 in the β chain [4].

Material and methods

In our laboratory, from January 1996 to January 2006, we characterised 17 families, which are not related to each other, that show ten haemoglobin variants or haemoglobinopathies with high oxygen affinity. The haemoglobinopathies were characterised either through electrophoresis in an alkaline pH (8.6 pH) cellulose acetate or an isoelectric focussing in polyacrylamide gel (5.5–8.5 pH) or agar citrate

(pH 6.0) electrophoresis or reverse-phase high-performance liquid chromatography (HPLC) for globin chains [5] or ionic-exchange HPLC [6]. Haemoglobin stability was determined using the isopropanol test [7], while the function was established through P_{50} in the oxygen balance curve plotted by a TCS Haemox-Analyser (TCS Medical Products Co., Huntingdon Valley, PA, USA) [8]. The molecular analysis was completed by automatic sequencing of the α and/or β genes' polymerase-chain-reaction-amplified products using the ABI Prism TM dRhodamine Terminator Cycle Sequencing Ready reagents kit (PE Applied Biosystems, Foster City, CA, USA) and the sequence was studied in an ABI Prism 310 Genetic Analyser (PE Applied Biosystems) [9, 10].

Results

All the demographic data, hematimetric results, P_{50} and chromatography findings are summarised in Table 1.

None of the patients in the study had any past or present clinical record of arterial or venous thrombosis at the time of diagnosis. All the referrals to our laboratory were due to erythrocytosis found, most often, during routine tests or through being relatives of the former patients. All patients were ethnically Caucasian and of Spanish origin.

Discussion

In haemoglobinopathies that show high oxygen affinity, the lower release of oxygen leads to tissue hypoxia that prompts erythropoietin output at renal level and induces both an increase in erythropoiesis and an offsetting secondary erythrocytosis [3].

In the haemoglobin structure, the $\alpha_1\beta_2$ bonds, the C-terminal ends of the β and α chains, the bonds to 2,3-DPG in the central cavity and the contact cavity with the haem group are significant zones not only for oxygen uptake but also for the 2,3-DPG, CO₂ and H⁺ allosteric effects over that uptake. Mutations experienced by amino acids enclosed in these zones, which are critical for haemoglobin functions, can therefore determine alterations in affinity to oxygen [11]. Of the ten high-affinity haemoglobinopathies found by our laboratory, in four (Hb San Diego, Hb Johnstown, Hb Malmö and Hb Columbia-Missouri), the amino acid change affects the $\alpha_1\beta_2$ contact zones [12–15], while in two (Hb Strasbourg and Hb Syracuse) the bonds to 2,3-DPG, in the central cavity, are affected [16, 17], and in another two (Hb Badalona and Hb La Coruña) the contact cavity to the haem group [18, 19] is affected and in one (Hb Bethesda) the $\alpha_1\beta_1$ contact zone is affected [20]. But, in the Hb Olympia, the amino acid change is located in site 20 of

Table 1 Haemoglobin variants with high oxygen affinity diagnosed in the Service of Haematology of Hospital Clínico San Carlos

| Fam | No of patients (age/sex) | Hb (g/dL) | Hct (%) | P_{50} (mmHg) | HPLC Hb | HPLC chains | Molecular mutation |
|-----------------|----------------------------|-----------|-----------|-----------------|---------|---------------------------------------|--|
| 1 ^a | 1 (50/V) | 20 | 58 | 13.2 | N | $\beta^X; \beta^A; \alpha$ | Hb Olympia [$\beta20(\text{B2})\text{Val}\rightarrow\text{Met}; \text{GTG}\rightarrow\text{ATG}]$ |
| 2 ^a | 1 (25/V) | 21.3 | 63.7 | 11 | HbX/HbA | $\beta^X; \beta^A; \alpha$ | Hb Syracuse [$\beta14-(\text{H21})\text{His}\rightarrow\text{Pro}; \text{CAC}\rightarrow\text{CCC}]$ |
| 3 ^b | 3 (54/V; 26/M; 19/N) | 13–17 | 44–52 | 21–22 | N | $\beta^X; \beta^A; \alpha$ | Hb San Diego [$\beta109(\text{G11})\text{Val}\rightarrow\text{Met}; \text{GTG}\rightarrow\text{ATG}]$ |
| 4 ^a | 1 (20/M) | 18.6 | 60.2 | 20 | N | $\beta^X; \beta^A; \alpha$ | Hb San Diego [$\beta109(\text{G11})\text{Val}\rightarrow\text{Met}; \text{GTG}\rightarrow\text{ATG}]$ |
| 5 ^a | 1 (52/M) | 16.7 | 48.2 | 14 | N | $\beta^X; \beta^A; \alpha$ | Hb San Diego [$\beta109(\text{G11})\text{Val}\rightarrow\text{Met}; \text{GTG}\rightarrow\text{ATG}]$ |
| 6 ^a | 1 (22/V) | 18.4 | 55 | 15 | N | $\beta^X; \beta^A; \alpha$ | Hb San Diego [$\beta109(\text{G11})\text{Val}\rightarrow\text{Met}; \text{GTG}\rightarrow\text{ATG}]$ |
| 7 ^b | 2 (74/V; 47/M) | 17–19 | 53–61 | 17–19 | N | $\beta^X; \beta^A; \alpha$ | Hb Johnstown [$\beta109(\text{G11})\text{Val}\rightarrow\text{Leu}; \text{GTG}\rightarrow\text{CTG}]$ |
| 8 ^a | 1 (32/M) | 15.3 | 45.8 | 20 | N | $\beta^X; \beta^A; \alpha$ | Hb Johnstown [$\beta109(\text{G11})\text{Val}\rightarrow\text{Leu}; \text{GTG}\rightarrow\text{CTG}]$ |
| 9 ^b | 4 (41/M; 11/M; 9/M; 5/M) | 14.2–17 | 46.6–50.2 | 16–19 | N | $\beta^X; \beta^A; \alpha$ | Hb Johnstown [$\beta109(\text{G11})\text{Val}\rightarrow\text{Leu}; \text{GTG}\rightarrow\text{CTG}]$ |
| 10 ^b | 4 (52/V; 26/M; 23/V; 21/V) | 17.5–19.6 | 53–57.5 | 14–19 | N | $\beta^X; \beta^A; \alpha$ | Hb Johnstown [$\beta109(\text{G11})\text{Val}\rightarrow\text{Leu}; \text{GTG}\rightarrow\text{CTG}]$ |
| 11 ^a | 2 (30/V; 27/M) | 18–19 | 60 | 13–15 | N | $\beta^X; \alpha \text{ No } \beta^A$ | Hb Johnstown + $\beta^0\text{Tal IVS-1-ntl (G}\rightarrow\text{A)}$ |
| 12 ^b | 2 (23/V; 53/M) | 17.3 | 49.2 | 12.5 | HbX/HbA | $\beta^X; \beta^A; \alpha$ | Hb Bethesda [$\beta145(\text{HC2})\text{Tyr}\rightarrow\text{His}; \text{TAT}\rightarrow\text{CAT}]$ |
| 13 ^c | 3 (17/M; 35/M; 666/M) | 17 | 48–49 | 22 | HbX/HbA | $\beta^X; \beta^A; \alpha$ | Hb Badalona [$\beta31(\text{B13})\text{Leu}\rightarrow\text{Val}; \text{CTG}\rightarrow\text{GTG}]$ |
| 14 ^a | 1 (66/V) | 15.9 | 49.5 | 21 | N | $\beta^X; \beta^A; \alpha$ | Hb Strasbourg [$\beta23(\text{B5})\text{Val}\rightarrow\text{Asp}; \text{GTT}\rightarrow\text{GAT}]$ |
| 15 ^a | 1 (25/V) | 18.4 | 55 | 17 | HbX/HbA | $\beta^X; \beta^A; \alpha$ | Hb Malmö [$\beta37(\text{F4})\text{His}\rightarrow\text{Glu}; \text{CAC}\rightarrow\text{CAA}]$ |
| 16 ^b | 4 (66/M; 59/V; 35/N; 29/M) | 16–18 | 50–55 | 16–21 | N | $\beta^A; \alpha; \beta^X$ | Hb Columbia-Missouri [$\alpha2\text{ 88Q(F9)}\text{Ala}\rightarrow\text{Val}; \text{GCG}\rightarrow\text{GTG}]$ |
| 17 ^b | 2 (22/V; 50/M) | 17–20 | 50–60 | 16–17 | N | $\beta^A; \beta^X; \alpha$ | Hb La Coruña [$\beta38(\text{C4})\text{Thm}^{\beta}\text{Ile}; \text{ACC}\rightarrow\text{ATC}]$ |

^a One generation

^b Two generations

^c Three generations

the chain helix B and there is no relation to any of the aforementioned zones, but it is accompanied by erythrocytosis. Replacement at this level of a polar amino acid, such as valine, by a hydrophobic one like methionine will most likely indirectly determine changes in some of those critical zones [21]. In this sense, another two haemoglobin variants affecting the site 20 of β chain Hb Trollhättan (Val→Glu) and Hb Uxbridge (Val→Gly) has been reported and in both variants there is an increase in oxygen affinity with mild erythrocytosis in the case of the Hb Trollhättan [22, 23]. In any event, an amino acid change, even through a different process, helps the haemoglobin quaternary structure to be stabilised in its relaxed configuration, thus reducing oxygen release and therefore lowering P_{50} in the oxygen dissociation curve.

Up to now, 89 haemoglobin variants that show high affinity for oxygen have been described: 18 in the α chain and 71 in the β one [4]. But two thirds of them are not accompanied by erythrocytosis, either because the affinity increase is slight or moderate and only found during *in vitro* studies or when molecular instability is present too, determining a concomitant haemolysis or if the mutating gene expression is low, as occurs in the α chain variations, or is reduced, as in Hb Crete [11]. Some erythrocytosis was found in all the patients reported in this paper or had been referred to our laboratory for that reason. But of the ten haemoglobinopathies, only one was found in an α chain variant. In a family affected by Hb Johnstown, an associated β^0 thalassaemia was found in two members due to IVS-1-nt1 (G→A) mutation. For this reason, all Hb was virtually Hb Johnstown in these patients. Most of the high-affinity haemoglobinopathies appear in heterozygotic individuals, while homozygotic cases are not reported, except for the Hb Tarrant found in an α chain and, for this reason, only 50% was quantified [24]. If the case found by our laboratory is added, high-affinity haemoglobinopathies associated to a β -thalassaemia are only found in five instances, all of them in a β chain and, for this reason, the Hb of these patients show high oxygen affinity. In such cases, as was to be expected, larger erythrocytosis levels are described, but significant clinical complications were not reported [11]. The notion that the homozygotic condition of variants with high oxygen affinity is incompatible to life can be questioned based on the aforementioned cases.

Erythrocytosis due to high-affinity haemoglobinopathies are usually fairly well tolerated by young patients, although thrombotic complications have been reported in elderly patients or when other vascular hazard factors are associated. Thrombotic complications have also been described for unstable variants that determine changes in the erythrocytic membrane of splenectomised patients, but none of the 34 patients in the study had either any acute clinical condition nor any thrombotic history [25, 26].

Although the high-affinity variants could in animal models determine an increase in foetal losses during pregnancy due to reduced oxygen release in the placenta, an increase in foetal losses has not been reported in families affected by high-affinity haemoglobinopathies.

Evidence of the pathological variant must be produced to diagnose secondary erythrocytosis in high-affinity haemoglobin variants. But over 30 of the aforementioned haemoglobinopathies remain undetected during conventional electrophoretic studies [11] for which reason chromatographic and molecular biology techniques have to be applied. In order to show the variant's high affinity for oxygen, however, a functional haemoglobin study is required. In all the patients studied, P_{50} was low but, in six of the ten variants found, the findings of electrophoretic and HPLC ionic-exchange studies were normal and only haemoglobin variants were disclosed by the reversed-phase HPLC.

A haemoglobin variant that shows high affinity for oxygen must be the suspected aetiology in families that report a history of erythrocytosis or young people, when there are no apparent reasons for this. Although it is rarely diagnosed, the 17 families reported that display ten different variants in the same geographic area lead us to think that the percentage of secondary erythrocytosis in haemoglobinopathies of this type could be even higher and therefore their systematic detection should be emphasised in erythrocytosis of unknown origin, more so when a family history is available.

Acknowledgments The following investigators and clinical departments belonging to the Erythropathology Cooperative Spanish Group have contributed to this study: A. del Arco (H. Doctor Pessel, Valencia); J.M. Vegae (H. Infanta Cristina, Badajoz); K. Atutxa (H. de Galdakao, Bilbao); B. Arrizabalaga (H. de Cruces, Bilbao); M. Ortega (H. Río Ortega, Valladolid); J. Juncá (H. Universitari Germans Trias i Pujol, Badalona); G. Martín-Núñez (H. Virgen del Puerto, Plasencia); A. Remacha (H. San Pau, Barcelona); I. San Roman (H. General Universitario de Guadalajara); P. de Andrés (H. Reina Sofía, Córdoba); S. Garzón (H. General de Jerez); B. Pérez de Mendiguren (H. General Yagüe, Burgos); C. Fernández Lago (H. Universitario Juan Canalejo, A Coruña); J. del Río (H. la Barbanza, A Coruña); M. Barbón (H. Virgen Blanca, León).

Funding from the European Commission for the “eInfrastructure for Thalassaemia Research Network” Coordination Action—Contract no 026539—for which this study was partially funded is gratefully acknowledged.

References

- Flint J, Harding RM, Boyce AJ, Clegg JB (1998) The population genetics of the haemoglobinopathies. *Baillieres Clin Haematol* 11(1):1–51 doi:10.1016/S0950-3536(98)80069-3
- Huisman THJ (1993) The structure and function of normal and abnormal haemoglobins. *Baillieres Clin Haematol* 6(1):1–30 doi:10.1016/S0950-3536(05)80064-2

3. Bunn HF, Forget BG (1986) Hemoglobin: molecular, genetic and clinical aspects. Saunders, Philadelphia
4. Hardison RC, Chui DH, Giardine B, Riemer C, Patrinos GP, Anagnou N et al (2002) HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. *Hum Mutat* 9(3):225–233 doi:[10.1002/humu.10044](https://doi.org/10.1002/humu.10044)
5. Riou J, Godart C, Hurtred D, Mathis M, Binet C, Bardakdjian-Michaau J et al (1997) Evaluation of cation-exchange high performance liquid chromatography for presumptive identification of hemoglobin variants. *J Clin Chem* 43:34–39
6. Shelton JB, Shelton JR, Schroder WA (1984) High performance liquid chromatography separation of globin chains on large-pore C₄ column. *J Liq Chromatogr* 7:1969–1977 doi:[10.1080/01483918408068849](https://doi.org/10.1080/01483918408068849)
7. Dacie JV, Lewis SM (1995) Practical Haematology, 8th edn. Churchill Livingstone, Edinburgh
8. Carreño DL, Sánchez J, González FA, Ropero P, Fdez-Lago C, Urkizu C et al (1999) Poliglobulias secundarias por hemoglobinoopatías. *Haematologica* 84:29
9. Martín G, Villegas A, González FA, Ropero P, Hojas R, Polo M et al (2005) A novel mutation of the α₂-globin causing alpha(+)-thalassemia: Hb Plasencia α125(H8)Leu→Arg (α2). *Hemoglobin* 29(2):113–117 doi:[10.1081/HEM-200058578](https://doi.org/10.1081/HEM-200058578)
10. Ropero P, Villegas A, Gonzalez AF, Anguita E, Sanchez J, Carreno DL et al (2000) Hb Johnstown [β109(G11)Val→Leu]: second case described and associated for the first time with beta (0)-thalassemia in two Spanish families. *Am J Hematol* 65 (4):298–301 doi:[10.1002/1096-8652\(200012\)65:4<298::AID-AJH8>3.0.CO;2-K](https://doi.org/10.1002/1096-8652(200012)65:4<298::AID-AJH8>3.0.CO;2-K)
11. Wajcman H, Galacteros F (2005) Hemoglobins with high oxygen affinity leading to erythrocytosis. New variants and new concepts. *Hemoglobin* 29(2):91–106 doi:[10.1081/HEM-200058571](https://doi.org/10.1081/HEM-200058571)
12. Nutt PE, Stamatoyannopoulos G, Hermodson MA, Roth D (1974) Hemoglobinopathic erythrocytosis due to a new electrophoretically silent variant, hemoglobin San Diego (β109(G11)Val→Met). *J Clin Invest* 53(1):320–328 doi:[10.1172/JCI107553](https://doi.org/10.1172/JCI107553)
13. Jones RT, Saiontz HI, Head C, Shih DT, Fairbanks VF (1990) Hb Johnstown [β109(G11)Val→Leu]: a new electrophoretically silent variant that causes erythrocytosis. *Hemoglobin* 14(2):147–156 doi:[10.3109/03630269009046956](https://doi.org/10.3109/03630269009046956)
14. Zak SJ, Geller GR, Kravit W, Tukey D, Brimhall B, Jones RT et al (1976) A hypothesis for the increased oxygen affinity in haemoglobin Malmö. *Br J Haematol* 33(1):101–104 doi:[10.1111/j.1365-2141.1976.tb00975.x](https://doi.org/10.1111/j.1365-2141.1976.tb00975.x)
15. Perry MC, Head C, Fairbanks VF, Jones RT, Taylor H, Proud V (1991) Hemoglobin Columbia Missouri or α₂[88(F9)Ala→Val]β₂: a new high-oxygen-affinity hemoglobin that causes erythrocytosis. *Mayo Clin Proc* 66(1):5–10
16. Bisce E, Schlemer E, Lizama M, Huaman-Guillen P, Wieland H, Adam G et al (1998) Hb Strasbourg [β23(B5)Val→Asp]; a high oxygen affinity variant observed in a German family. *Hemoglobin* 22(1):69–73
17. Jensen M, Osaki FA, Nathan DG, Bunn HF (1975) Hemoglobin Syracuse (α₂β₂-143(H21)His leads to Pro), a new high-affinity variant detected by special electrophoretic methods. Observations on the auto-oxidation of normal and variant hemoglobins. *J Clin Invest* 55(3):469–477 doi:[10.1172/JCI107953](https://doi.org/10.1172/JCI107953)
18. Juncá J, Villegas A, Ropero P, Gonzalez FA, Motos A, Valverde F (2002) Characterization of a new hemoglobin variant: Hb Badalona β31(B13)Leu→Val. *Ann Hematol* 81(4):179–181 doi:[10.1007/s00277-002-0447-6](https://doi.org/10.1007/s00277-002-0447-6)
19. Ropero P, Fernandez-Lago C, Villegas A, Polo M, Mateo M, Mora A et al (2006) Hb La Coruña [β38(C4)Thr→Ile]: a new hemoglobin variant leading to familial polycythemia. *Hemoglobin* 30(3):379–383 doi:[10.1080/03630260600755666](https://doi.org/10.1080/03630260600755666)
20. Bunn HF, Bradley TB, Davis WE, Drysdale JW, Burke JF, Beck WS et al (1972) Structural and functional studies on hemoglobin Bethesda (α₂β₂145His), a variant associated with compensatory erythrocytosis. *J Clin Invest* 51(9):2299–2309 doi:[10.1172/JCI107040](https://doi.org/10.1172/JCI107040)
21. Stamatoyannopoulos G, Nutt PE, Adamson JW, Bellingham AJ, Funk D (1973) Hemoglobin Olympia (20 valine leads to methionine): an electrophoretically silent variant associated with high oxygen affinity and erythrocytosis. *J Clin Invest* 52(2):342–349 doi:[10.1172/JCI107190](https://doi.org/10.1172/JCI107190)
22. Wajcman H, Prome D, Kister J, Davies SC, Galacteros F, Henthon JS (1996) Hb Uxbridge [β20(B2)Val→Gly]: a new variant with mild increase in oxygen affinity found during a neonatal screening program. *Hemoglobin* 20(4):339–350 doi:[10.3109/03630269609005838](https://doi.org/10.3109/03630269609005838)
23. Landin B, Berglund S, Lindoff B (1994) Hb Trollhattan [β20(B2) Val[®]Glu] a new haemoglobin variant with increased oxygen affinity causing erythrocytosis. *Eur J Haematol* 53(1):21–25
24. Ibarra B, Vaca G, Cantu JM, Wilson JB, Lam H, Stallings M et al (1981) Heterozygosity and homozygosity for the high oxygen affinity hemoglobin Tarrant or alpha 126 (H9) Asp replaced by Asn in two Mexican families. *Hemoglobin* 5(4):337–348 doi:[10.3109/03630268108991808](https://doi.org/10.3109/03630268108991808)
25. Dash S, Das R (2004) Late emergence of polycythemia in a case of Hb Chandigarh β94(FG1)Asp→Gly. *Hemoglobin* 28(3):273–274 doi:[10.1081/HEM-120040311](https://doi.org/10.1081/HEM-120040311)
26. Kister J, Baudin-Creuz V, Kiger L, Prehu C, Papassotiriou I, Riou J et al (2005) Hb Montfermeil [β130(H8)Tyr→Cys]: suggests a key role for the interaction between helix A and H in oxygen affinity of the hemoglobin molecule. *Blood Cells Mol Dis* 34(2):166–173 doi:[10.1016/j.bcmd.2004.12.003](https://doi.org/10.1016/j.bcmd.2004.12.003)